Edition:
United States

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

46.25USD
21 May 2018
Change (% chg)

-- (--)
Prev Close
$46.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
349,594
52-wk High
$47.64
52-wk Low
$12.25

Chart for

About

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the... (more)

Overall

Beta: 1.52
Market Cap(Mil.): $2,327.93
Shares Outstanding(Mil.): 49.23
Dividend: --
Yield (%): --

Financials

  ARNA.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -3.01 -- --
ROI: -28.52 -8.07 12.63
ROE: -33.93 -10.87 14.50

BRIEF-Arena Pharmaceuticals Reports Q1 Loss Per Share $0.80

* EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018

May 08 2018

BRIEF-Arena Pharmaceuticals To Release Q1 Financial Results And Provide Corporate Update On Tuesday, May 8

* ARENA PHARMACEUTICALS TO RELEASE FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON TUESDAY, MAY 8 Source text for Eikon: Further company coverage:

May 02 2018

BRIEF-Arena Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* ARENA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Mar 21 2018

BRIEF-Arena Pharmaceuticals To Offer 7.5 Mln Shares Of Its Common Stock In An Underwritten Public Offering

* ARENA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 20 2018

Arena Pharma's bowel disease drug meets study goal, shares surge

Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.

Mar 19 2018

UPDATE 1-Arena Pharma's bowel disease drug meets study goal, shares surge

March 19 Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.

Mar 19 2018

BRIEF-Arena Pharmaceuticals Q4 Loss Per Share $0.35

* ARENA PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Mar 14 2018

BRIEF-Arena Pharma, Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China

* ARENA PHARMACEUTICALS AND EVEREST MEDICINES ENTER INTO DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP FOR RALINEPAG AND ETRASIMOD IN CHINA

Dec 05 2017

Competitors

Earnings vs. Estimates